Genitourinary tract infections and SGLT2 inhibitors in heart failure: an EMPEROR-Pooled analysis
- 28 February 2026
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 28 (3) , 448-457
Abstract
Aims: Sodium glucose co-transporter-2 inhibitors (SGLT2i) improve outcomes of patients with heart failure (HF). Urinary tract infections (UTI) are relatively common in HF, and their occurrence has been associated with an increased mortality risk. The use of SGLT2i has been associated with the occurrence of UTIs and mycotic genitourinary infections (MGI) which are a major cause of treatment discontinuation. This study aimed to study genitourinary infections in men and women with HF, their association with outcomes, and the impact of empagliflozin. Methods: Analysis of EMPEROR-Pooled including a total of 9718 patients across the spectrum of ejection fraction. Descriptive statistics, Cox and time-varying survival models were used. The median follow-up time was 21 months. Results: Throughout follow-up, 757 (7.8%) patients experienced a lower UTI, 60 (0.6%) MGI, and 41 pyelonephritis/urosepsis (0.4%). Genitourinary infections were more frequent in women than in men. Compared to patients without UTI/MGI, those with pyelonephritis/urosepsis were older and had higher comorbidity burden, whereas those with MGI were younger and had a higher prevalence of diabetes and obesity. Compared to placebo, empagliflozin was associated with a higher risk of lower UTI and MGI, particularly balanitis in men, but not pyelonephritis/urosepsis. The risk of death increased after UTI, but not after MGI. The effect of empagliflozin versus placebo on the composite of HF hospitalization or cardiovascular death was not modified by the occurrence of genitourinary infections. Conclusions: Lower UTIs were relatively frequent in HF patients, whereas MGI and pyelonephritis/urosepsis were infrequent. SGLT2i increased the risk of lower UTI and MGI. Although UTI, but not MGI, were associated with a higher subsequent risk of death, the clinical benefits of SGLT2i were preserved regardless of genitourinary infection occurrence.Keywords
Funding Information
- Boehringer Ingelheim
- Eli Lilly Australia
This publication has 16 references indexed in Scilit:
- Sodium-Glucose Cotransporter 2 Inhibitors and Mycotic Genital or Urinary Tract Infections in Heart FailureJournal of Cardiac Failure, 2024
- Empagliflozin and Risk of Lower Respiratory Tract Infection in Heart Failure with Mildly Reduced and Preserved Ejection Fraction: An EMPEROR-Preserved AnalysisEuropean Journal of Heart Failure, 2024
- Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trialsThe Lancet, 2022
- SGLT2-inhibitors are effective and safe in the elderly: The SOLD studyPharmacological Research, 2022
- Risk factors of first and recurrent genitourinary tract infection in patients with type 2 diabetes treated with SGLT2 inhibitors: A retrospective cohort studyDiabetes Research and Clinical Practice, 2022
- Empagliflozin in Heart Failure with a Preserved Ejection FractionNew England Journal of Medicine, 2021
- Empagliflozin and Major Renal Outcomes in Heart FailureNew England Journal of Medicine, 2021
- Design of a Prospective Patient-Level Pooled Analysis of Two Parallel Trials of Empagliflozin in Patients with Established Heart FailureEuropean Journal of Heart Failure, 2020
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureNew England Journal of Medicine, 2020
- Late urinary tract infection after renal transplantation in the United StatesAmerican Journal of Kidney Diseases, 2004